Article citationsMore>>
Oneal, P.A., Kwitkowski, V., Luo, L., Shen, Y.L., Subramaniam, S., Shord, S., Goldberg, K.B., McKee, A.E., Kaminskas, E., Farrell, A. and Pazdur, R. (2018) FDA Approval Summary: Vemurafenib for the Treatment of Patients with Erdheim-Chester Disease with the BRAFV600 Mutation. The Oncologist, 23, 1520-1524.
https://doi.org/10.1634/theoncologist.2018-0295
has been cited by the following article:
Related Articles:
-
Ning Li, Mingquan Chen, Huaping Sun, Yun Bao, Jiming Zhang
-
Ivo De Menezes, Filadélfia Martins, Rosineli Oliveira, Victor Meireles, Felipe Nobre
-
Wenzhi Hao, Qian Chen, Feifei Xue
-
Emad Mohsen Barsoum, Fiby Samir Boules, May Gamal Ashour, Mohsen Samy Barsoum
-
Hiromitsu Takano, Takatoshi Okuda, Ikuho Yonezawa, Kazuo Kaneko